Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance

Heron Therapeutics IncTrade
iShares Broad USD Investment Grade Corporate BondTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Heron Therapeutics Inc trades at $0.33 (market cap $63.41M), while iShares Broad USD Investment Grade Corporate Bond trades at $50.2. Which is the better fit depends on your goals.

HRTXUSIG
Market Cap
$63.41M
Sector
HealthFixed Income
52-Week High
$1.49$52.69
52-Week Low
$0.32$50.18
Enterprise Value
$161.31M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

iShares Broad USD Investment Grade Corporate Bond

USIG trades at $50.40 with minimal daily movement (+0.16%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The company maintains consistent dividend distributions, with recent payouts of $0.20-$0.21 per share. Recent news includes AM Best affirming credit ratings for subsidiaries following a transaction with Tiptree Inc.

Investment outlook remains cautious given bearish technical signals and limited fundamental data availability. The steady dividend history provides income appeal, but investors face uncertainty from incomplete financial metrics. Key risks include potential volatility from institutional positioning changes and transaction integration challenges with Tiptree.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About iShares Broad USD Investment Grade Corporate Bond

USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.

Read more on USIG